Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,041,909 | -19.7% | 191,176 | 0.0% | 4.24% | +3.5% |
| Q2 2023 | $1,298,276 | +35.5% | 191,176 | 0.0% | 4.10% | +39.5% |
| Q1 2023 | $957,792 | +2.7% | 191,176 | 0.0% | 2.94% | -4.6% |
| Q4 2022 | $932,939 | -66.2% | 191,176 | 0.0% | 3.08% | -67.2% |
| Q3 2022 | $2,757,000 | -4.7% | 191,176 | 0.0% | 9.37% | -1.9% |
| Q2 2022 | $2,892,000 | +27.3% | 191,176 | 0.0% | 9.56% | +263.4% |
| Q1 2022 | $2,271,000 | -26.7% | 191,176 | 0.0% | 2.63% | +35.1% |
| Q4 2021 | $3,099,000 | -49.9% | 191,176 | -11.9% | 1.95% | -49.5% |
| Q3 2021 | $6,191,000 | -15.6% | 216,916 | 0.0% | 3.86% | -19.5% |
| Q2 2021 | $7,332,000 | +11.8% | 216,916 | 0.0% | 4.79% | +18.6% |
| Q1 2021 | $6,560,000 | -38.9% | 216,916 | 0.0% | 4.04% | -11.1% |
| Q4 2020 | $10,740,000 | – | 216,916 | – | 4.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |